Levodopa-carbidopa intestinal gel
Sponsors
AbbVie (prior sponsor, Abbott), AbbVie
Conditions
Advanced Parkinson's DiseaseDyskinesiasParkinson's DiseaseSevere Motor Fluctuations
Phase 3
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
CompletedNCT00335153
Start: 2008-01-31End: 2012-06-30Updated: 2015-01-16
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
CompletedNCT00360568
Start: 2009-06-30End: 2012-10-31Updated: 2015-01-16
A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease
CompletedNCT01736176
Start: 2013-03-31End: 2015-12-31Updated: 2021-07-16
A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
CompletedNCT01960842
Start: 2013-10-31End: 2015-03-31Updated: 2018-05-30
A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)
CompletedNCT02549092
Start: 2015-10-26End: 2022-11-18Updated: 2023-11-28